ERBB2 and lymphangioleiomyomatosis: More than three studies enrolled participants with breast cancer, including HER2-negative breast cancer and lymph node-positive breast cancer.383–385 A few studies recruited participants with other diseases, including lung adenocarcinoma,386 early squamous cell carcinomas of the oral cavity and oropharynx, Type 1 diabetes,252 tongue cancer,387 lower limb lymphedema, lymphangioleiomyomatosis (LAM)388 and pulmonary tuberculosis.